Host-Based Th2 Cell Therapy for Prolongation of Cardiac Allograft Viability
Author Information
Author(s): Amarnath Shoba, Chen Hao, Foley Jason E., Costanzo Carliann M., Sennesh Joel D., Solomon Michael A., Fowler Daniel H.
Primary Institution: National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America
Hypothesis
Adoptive transfer of immune regulatory host Th2 cells would represent a novel intervention to enhance cardiac allograft survival.
Conclusion
Host-type Th2.R cell therapy prior to cardiac allografting can prolong allograft viability when used in combination with short-course cyclosporine therapy.
Supporting Evidence
- Th2.R cell therapy reduced the frequency of activated T cells in secondary lymphoid organs.
- Th2.R cell therapy shifted post-transplant cytokines towards a Th2 phenotype.
- Th2.R cell therapy prolonged allograft viability when used in combination with short-course CSA therapy.
Takeaway
This study shows that using special immune cells from the host can help keep transplanted hearts alive longer.
Methodology
The study used a rat cardiac transplant model to evaluate the effects of host Th2 cell therapy and cyclosporine on allograft survival.
Limitations
The study did not assess the long-term effects of Th2 cell therapy on allograft viability.
Participant Demographics
Inbred male brown Norway (BN) and dark agouti (DA) rats, weighing 200–250 g.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website